Debt to Equity Ratio Chart

Historical Debt to Equity Ratio Data

View and export this data back to 2013. Start Trial.
Date Value
June 30, 2026 0.0264
March 31, 2026 0.0576
December 31, 2025 0.0607
September 30, 2025 0.2034
June 30, 2025 0.2058
March 31, 2025 0.2809
December 31, 2024 0.2861
September 30, 2024 0.7506
June 30, 2024 -1.154
March 31, 2024 -1.208
December 31, 2023 -1.128
September 30, 2023 4.690
June 30, 2023 1.851
March 31, 2023 1.519
December 31, 2022 1.957
September 30, 2022 1.108
June 30, 2022 0.6595
March 31, 2022 0.7517
December 31, 2021 0.6109
September 30, 2021 0.7446
June 30, 2021 0.6184
March 31, 2021 0.5108
December 31, 2020 1.078
September 30, 2020 1.255
Date Value
June 30, 2020 1.110
March 31, 2020 0.1833
December 31, 2019 0.736
September 30, 2019 -2.361
June 30, 2019 2.094
March 31, 2019 0.9311
December 31, 2018 0.5729
September 30, 2018 0.4867
June 30, 2018 0.3054
March 31, 2018 0.1591
December 31, 2017 0.9251
September 30, 2017 0.3671
June 30, 2017 -0.9244
March 31, 2017 2.305
December 31, 2016 0.4277
September 30, 2016 0.4556
June 30, 2016 0.2055
March 31, 2016 0.4653
December 31, 2015 0.2176
September 30, 2015 0.1294
June 30, 2015 0.0376
March 31, 2015 -0.9293
December 31, 2013 2.081

Debt to Equity Ratio Definition

The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.

Read full definition.

Debt to Equity Ratio Range, Past 5 Years

View Debt to Equity Ratio Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Debt to Equity Ratio Benchmarks

View Debt to Equity Ratio Benchmarks
Start Trial
Phio Pharmaceuticals Corp. 0.00
Agenus, Inc. -1.458
Amgen, Inc. 3.763
Anika Therapeutics, Inc. 0.1839
BioCryst Pharmaceuticals, Inc. -2.084